Clinical Trial Update: BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Clinical trial results for Sorafenib (BAY 43-9006) in relapsed non-small cell lung cancer (Phase 2) have been posted following completion of the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non-Small-Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2012-05-02